GENZYME CORP
Healthcare · Biological Products, (No Diagnostic Substances) · MA · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY10 | FY09 | FY08 | FY07 | |
|---|---|---|---|---|
| Revenue | $941.9M | $4.52B | $4.61B | $3.81B |
| Operating income | $35.8M | $503.7M | $581.5M | $653.9M |
| Net income | −$114.9M | $422.3M | $421.1M | $480.2M |
| Total assets | $10.91B | $10.06B | $8.67B | — |
| Total liabilities | $3.33B | $2.38B | $1.37B | — |
| Equity | $7.59B | $7.68B | $7.31B | $6.61B |
| EPS (diluted) | $-0.43 | $1.54 | $1.50 | $1.74 |
| Shares out. | 266.1M | 265.7M | 285.6M | 280.8M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2010- Operating margin
- 3.8%
- Net margin
- −12.2%
- Return on equity
- −1.5%
- Return on assets
- −1.1%
- Return on capital (ROCE)
- 0.4%
- Liabilities / assets
- 30.5%
- Debt / equity
- 0.44×
- Book value / share
- $28.51
- Revenue growth (YoY)
- −79.1%
- Net income growth (YoY)
- −127.2%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2010- Altman Z″ (distress)
- 4.48safe
- Accruals / assets
- −5.5%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 2 warning● 5 good- Reported a net loss
- Revenue declined year-over-year
- Operating margin is positive
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
FDA-approved drugs
openFDA · most recent- LUMIZYMEMay 24, 2010
- RENVELAAug 12, 2009
- MOZOBILDec 15, 2008
- MYOZYMEApr 28, 2006
- CLOLARDec 28, 2004
- FABRAZYMEApr 24, 2003
- LEUPROLIDE ACETATENov 29, 2001
- LEMTRADAMay 7, 2001
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2019-09-30A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa
- Phase 3Active Not Recruitingreadout ~2026-08-15Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B
- Phase 4Active Not Recruitingreadout ~2026-09-30Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)
- Phase 2Active Not Recruitingreadout ~2026-10-30Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension
- Phase 3Active Not Recruitingreadout ~2026-11-05Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII or IX
- Phase 4Recruitingreadout ~2028-05-02China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Sanofi-Aventis10% owner | Apr 6, 2011 | Buy | 3.9M | — |
| Berthiaume Douglas ADirector | Apr 4, 2011 | U | 4,048 | $74.00 |
| Berthiaume Douglas ADirector | Apr 4, 2011 | Option exercise | 2,375 | $0.00 |
| Mcgillicudy Cornelius IiiDirector | Apr 4, 2011 | Option exercise | 2,375 | $0.00 |
| Dzau Victor JDirector | Apr 4, 2011 | Option exercise | 2,375 | $0.00 |
| Cooney Charles LDirector | Apr 4, 2011 | Option exercise | 3,827.389 | $0.00 |
| Whitworth Ralph VDirector | Apr 4, 2011 | Option exercise | 2,375 | $0.00 |
| Ende Eric JDirector | Apr 4, 2011 | Option exercise | 2,375 | $0.00 |
| Carpenter Robert JDirector | Apr 4, 2011 | Option exercise | 2,375 | $0.00 |
| Burakoff StevenDirector | Apr 4, 2011 | Option exercise | 2,375 | $0.00 |
| Syron Richard F/CaDirector | Apr 4, 2011 | Option exercise | 2,375 | $0.00 |
| Fenton Dennis MDirector | Apr 4, 2011 | Option exercise | 2,375 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Unregistered equity sale · Modified shareholder rights · Change in control · Director / officer changeApr 8, 2011
- Other material eventMar 30, 2011
- Entered a material agreement · Results of operations · Other material eventFeb 16, 2011
- Entered a material agreementFeb 1, 2011
- Results of operationsJan 11, 2011
- Costs from exit or disposalNov 5, 2010
- Results of operationsOct 20, 2010
- Entered a material agreement · Other material eventSep 13, 2010
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12GFORM 15Apr 18, 2011
- EFFECTApr 14, 2011
- EFFECTApr 14, 2011
- EFFECTApr 14, 2011
- EFFECTApr 14, 2011
- SC 13DSCHEDULE 13DApr 13, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-167873Apr 13, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-167872Apr 13, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-167871Apr 13, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-165604Apr 13, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-160398Apr 13, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-160397Apr 13, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-153898Apr 13, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-143469Apr 13, 2011
- S-8 POSPOST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-143468Apr 13, 2011
Event-driven situations (4)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.